In the Interim... cover art

All Episodes

In the Interim... — 78 episodes

#
Title
1

The CHIPS Trial: Bayesian Adaptive Trial in JAMA

2

NFL Study of CTE: The Issues

3

Talkin' 'bout Sweet Time

4

Mammograms: Death Threats, Hillary Clinton and Lead-Time Bias

5

REMAP-CAP Results: Oseltamivir in Critically-Ill Influenza Patients

6

ICECAP: The Results

7

Failure of the Proportional Odds is the Result

8

Adaptive Design Actions Matrix

9

A Visit With Tim Berry

10

Fairness in Soccer and Clinical Trials

11

Bias in Stopping Trials Early

12

A Statistician Reads JAMA: A Futile Issue

13

Response-Adaptive Randomization in Clinical Trials

14

REMAP-CAP: The Origin

15

Fighting Time in Adaptive Trials

16

ICECAP: The Adaptive Design

17

Multi-Platform RCT

18

Sports and Clinical Trials: The 1927 Yankees, 15 Tarzans, and Modern Athletes

19

AI @ Berry

20

Drug Development and Sports: The 10-Run Rule and Futility

21

ICH-E20, Regulators, and False Choices

22

PANTHER: A Phase 2 International Platform Trial in ARDS

23

A Visit with Byron Gajewski: KUMC, Innovative Trial Designs, the HOBIT Trial

24

A Visit with Stephen Senn: Time, Concurrent Controls, and the Bayesian Guidance

25

Making Sense of Hierarchical Composites

26

The SNAP Trial with Professors Tong and Davis

27

Bayesian Borrowing in Phase 3 Trials

28

The Art of Storytelling with Shaun Cassidy

29

The Fallacy of Ordinal Endpoints

30

Mr. Berry Goes to Washington

31

Platform Trial in Orthopaedic Surgery

32

A Visit with Michael Harhay

33

The FDA Bayesian Guidance

34

Path 2 Parkinson's Prevention with Drs. Simuni and Wendelberger

35

Statistical Communication

36

The Rumor of One Trial for Substantial Evidence

37

Communication for Scientists: A Discussion with Jenny Devenport

38

Navigating the Arena: Platform Trials

39

Jumping Hurdles: Interim Analyses for Funding Decisions

40

Discussion with Kaspar Rufibach

41

Bayesian Statistics in Clinical trials: The Past, Present, and Future

42

A Visit with Stroke Neurologist Dr. Jeff Saver

43

The Saga of the Lecanemab Adaptive Phase II Trial

44

Teaching Statistics and Data Science through Sports with Dr. Jim Albert

45

Digital Googols

46

A Visit with Andrew Thomson

47

Moving Clinical Trial Goalposts

48

The Not So Promising Zone Design

49

A Visit with Dr. Janet Wittes

50

Bayesian Clinical Trials with Frank Harrell

51

A Visit with Dr. Derek Angus

52

The Mystery of Clinical Trial Simulation

53

Discussions on the ICH E20 Draft Guidance

54

A Discussion with Michael Proschan on Response-Adaptive Randomization

55

STEP Statistical Modeling

56

Bayesian Approach in Clinical Trials

57

The Time Machine

58

The Legend of I-SPY 2 - Part B

59

The Legend of I-SPY 2 - Part A

60

The STEP Platform with Dr. Eva Mistry and Dr. Jordan Elm

61

A Statistician reads JAMA

62

Seamless 2/3 Trial Designs

63

Spending Alpha

64

Prof Craig Ritchie: Looking Back at EPAD, moving forward in Alzheimer's Disease

65

Drug Developers' Lessons from Sports: Regression-to-the-Mean

66

DSMBs in Adaptive Trials with Roger Lewis

67

Platform Trial in Psychiatry with Dr. Husseini Manji

68

Implementing Adaptive Trials

69

Revisiting Seamless 2/3 Trial for GLP-1 Agonist

70

I-SPY 2 to GBM AGILE and Beyond

71

External Data in Clinical Trials

72

Remembering Jimmie Savage

73

The Art and Slog of Innovating

74

Religion, Politics, and Ordinal Outcomes

75

HEALEY ALS Platform Trial with Dr. Merit Cudkowicz and Dr. Melanie Quintana

76

FACTS 7.1 Release with Tom Parke

77

When should you use adaptive design clinical trials?

78

The Story of Berry Consultants